Could a pill keep AML at bay? new study tests maintenance therapy after chemo

NCT ID NCT06349239

Completed Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether taking oral azacitidine (Onureg) as maintenance therapy can help older adults with acute myeloid leukemia (AML) stay in remission longer after treatment with CPX-351 chemotherapy. The study included 100 patients aged 65 and older who had achieved remission. Researchers tracked overall survival and side effects to see if this approach is safe and effective for those who cannot undergo a stem cell transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral azacitidine (Onureg)
What this could lead to: If successful, this could provide a way to keep AML in remission longer for older patients who cannot have a stem cell transplant.
What could go wrong: This is a small, completed study with no control group, so results may not be definitive. Oral azacitidine can cause side effects like nausea or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia with multilineage dysplasia therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

CHU de Nice

Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.